Matteo Trotta - 15 Jul 2024 Form 4 Insider Report for INCYTE CORP (INCY)

Role
EVP, GM, Dermatology US
Signature
/s/ Elizabeth Feeney, Attorney-In-Fact
Issuer symbol
INCY
Transactions as of
15 Jul 2024
Net transactions value
$0
Form type
4
Filing time
17 Jul 2024, 12:28:41 UTC
Previous filing
27 Mar 2024
Next filing
22 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INCY Common Stock Award $0 +2,646 +34% $0.000000 10,474 15 Jul 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INCY Employee Stock Option (right to buy) Award $0 +5,921 $0.000000 5,921 15 Jul 2024 Common Stock 5,921 $64.25 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2 Including the July 15, 2024 grant, this includes an aggregate of 10,474 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3 The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.